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Abstract
Pro-survival members of the Bcl-2 protein family inhibit cell death by binding short helical BH3
motifs in pro-apoptotic proteins. Mammalian pro-survival proteins Bcl-xL, Bcl-2, Bcl-w, Mcl-1
and Bfl-1 bind with varying affinities and specificities to native BH3 motifs, engineered peptides
and small molecules. Biophysical studies have determined interaction patterns for these proteins,
particularly for the most-studied family members Bcl-xL and Mcl-1. Bfl-1 is a pro-survival protein
implicated in preventing apoptosis in leukemia, lymphoma and melanoma. Although Bfl-1 is a
promising therapeutic target, relatively little is known about its binding preferences. We explored
the binding of Bfl-1 to BH3-like peptides by screening a peptide library that was designed to
sample a high degree of relevant sequence diversity. Screening using yeast-surface display led to
several novel high-affinity Bfl-1 binders and to thousands of putative binders identified through
deep sequencing. Further screening for specificity led to identification of a peptide that bound to
Bfl-1 with Kd < 1 nM and very slow dissociation from Bfl-1 compared to other pro-survival Bcl-2
family members. A point mutation in this sequence gave a peptide with ~50 nM affinity for Bfl-1
that was selective for Bfl-1 in equilibrium binding assays. Analysis of engineered Bfl-1 binders
deepens our understanding of how the binding profiles of pro-survival proteins differ, and may
guide the development of targeted Bfl-1 inhibitors.
Introduction
Interactions among Bcl-2 family proteins play a critical role regulating apoptosis. The
family is divided into two major subclasses: (1) pro-survival and (2) pro-apoptotic Bcl-2
proteins. The pro-survival proteins that include Bcl-xL, Mcl-1, Bcl-2, Bcl-w and Bfl-1 are
responsible for antagonizing the activities of pro-apoptotic proteins and thereby inhibiting
apoptosis. Among pro-apoptotic proteins, Bax and Bak are downstream effectors of cell
death. They form pores in the mitochondrial outer membrane that mediate the release of
cytochrome c, with subsequent activation of executioner caspases(1). Another class of pro-
apoptotic proteins, the BH3-only proteins, functions to relieve the inhibitory effect of the
pro-survival proteins by binding to them(2). Prominent members of this family include the
proteins Bim, Bid, Puma, Noxa, Bad, Bmf, Hrk, Bik and Mule. Interestingly, BH3-only
proteins exhibit a range of affinities for pro-survival proteins, and disrupting the balance of
interacting partners modulates signaling thresholds for apoptosis(3).
Pro-survival proteins are frequently over-expressed in cancer cells(4). Bcl-xL, Bcl-2 and
Mcl-1 are attractive therapeutic targets due to their association with aggressive malignant
phenotypes and drug resistance to various chemotherapeutic agents(5, 6). However, Bfl-1,
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which has an important function in the hematopoietic system(7, 8), is less well studied.
Increased expression of Bfl-1 has been associated with different forms of leukemia and
lymphoma(9), and over-expression of Bfl-1 mRNA has been identified in solid tumor tissues
of varying origins including breast, colon, lung, ovarian and prostate(10). In addition, Bfl-1 is
associated with metastatic disease in melanoma(11) and hepatocellular carcinoma(12), and
RNAi targeting of Bfl-1 along with Mcl-1 in melanoma cell lines leads to enhanced cell
death without affecting non-malignant cells(13). A role for Bfl-1 in tumor progression is
indicated by its expression in advanced tumor stages(14). Furthermore, increased expression
of Bfl-1 has been shown to correlate with chemo-resistance in leukemia and breast
cancer(15, 16). These studies highlight the therapeutic potential of Bfl-1 inhibitors(7).
There have been conflicting reports regarding the pro-apoptotic interaction partners of Bfl-1.
Bfl-1 has been reported to inhibit cell death associated with Bak activation(17), though the
extent of interaction of Bfl-1 with both Bak and Bax is disputed(18–21). Peptides
corresponding to the BH3 motifs of Bim, Puma and Bid, hereafter called Bim BH3, Puma
BH3, etc., have been reported to bind tightly to Bfl-1, with dissociation constants of ~50 nM
in vitro(3, 22). Binding of the BH3 motif from Noxa, and to a lesser extent the motifs from
Bik and Hrk, has also been reported(3, 23). Interaction with Noxa BH3 and non-interaction
with Bad BH3 makes Bfl-1 somewhat similar to Mcl-1 in terms of its BH3-peptide binding
profile. In addition, the BH3 mimetic small molecule ABT-737 does not bind tightly to
Bfl-1 or Mcl-1, despite having high affinity for Bcl-xL, Bcl-2 and Bcl-w(23–25). Therefore, in
cells over-expressing Bfl-1/Mcl-1, treatment with ABT-737 only leads to cell death if Bfl-1/
Mcl-1 are separately neutralized with other BH3 proteins(3). A recent study with peptide
aptamers identified molecules that bound Bfl-1 and initiated cell-death in lymphoma B-cell
lines(26).
Crystal structures of Bfl-1 in complex with peptides corresponding to the BH3 motifs of
pro-apoptotic proteins show a conserved binding mode shared with other pro-survival family
members(18, 27, 28). A surface groove on Bfl-1 engages an amphipathic BH3 helix of ~16 –
25 residues. Positions on the BH3 helix, which follow a loose 7-residue hydrophobic/polar
repeat, are often designated a – g, as shown for a peptide derived from Bim binding to Bfl-1
in Fig. 1a and b. There are differences in the binding groove of Bfl-1 compared to other
family members. For example, Bfl-1 has a highly atypical glutamate residue at a position
that is typically occupied by valine or leucine in other pro-survival proteins. This contributes
to making the Bfl-1 groove slightly negatively charged, in contrast to the groove of Mcl-1,
which is slightly positively charged(27–29). Overall, the sequence identity between Mcl-1 and
Bfl-1 is only 21.4%, and the similarity with other pro-survival proteins is even lower.
Despite an emerging appreciation of the importance of Bfl-1, a good understanding of its
BH3-binding specificity is lacking. In this study, we isolated high affinity BH3-like peptides
that bound to Bfl-1 by screening a combinatorial peptide library that was computationally
designed based on published experimental data. Combining screening and rational design,
we identified a peptide that bound tightly to Bfl-1 in preference to interacting with pro-
survival proteins Bcl-xL, Bcl-2, Bcl-w and Mcl-1. Mutational and structural analyses
highlighted positions important for preferential binding.
Results and Discussion
Computational library design
We based our peptide designs on the BH3 region of human Bim, which is reported to bind
strongly to Bfl-1 (Fig. 1a, b)(3, 18, 22). Although the BH3 region of Noxa interacts
preferentially with Mcl-1 and Bfl-1 over Bcl-xL, Bcl-w and Bcl-2, potentially making it an
appealing starting point for design, Noxa BH3 binding to Bfl-1 is weaker than that of Bim
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BH3(3, 18). Furthermore, SPOT array binding data are available for hundreds of point
mutants of Bim BH3, and we chose to use these data to guide our design procedure(30–32).
An image of a Bim BH3 substitution SPOT array probed with 100 nM Bfl-1 is shown in Fig.
1c(32). Based on such array data for Bim BH3 point mutants, we developed position specific
scoring matrices (PSSMs) for predicting the binding of BH3-like peptides to all five
proteins(31, 32). For example, model PSSMBfl-1, derived from the data in Fig. 1c, can be used
to score binding of BH3-like peptides to Bfl-1. We developed a computational approach
guided by the PSSM models to design a combinatorial library enriched in sequences
predicted to bind tightly and selectively to Bfl-1.
In the first step of library design (Fig. 1d), we defined two classes of mutations: non-
disruptive and specific. A single-residue substitution was defined as non-disruptive if its
Bfl-1 PSSM score was among the top 50% of the Bfl-1 binding scores for all amino acids
across all positions tested. A non-disruptive mutation was further classified as specific if it
was ranked in the top 33% of mutations that favored binding to Bfl-1 over another pro-
survival protein (see Methods). Four types of specificity mutations (Bfl-1 over Bcl-xL/
Mcl-1/Bcl-2/Bcl-w) were defined (Table 1). Substitutions at positions 2d, 2e, 2g, 3a, 3d, 3g
and 4a (Fig. 1a and b) met our criteria for being specific and non-disruptive, therefore, we
constructed our library using a set of degenerate codons to maximize diversity at these
positions (see Methods).
The diversity of the optimized library, which had a theoretical size of 8.9 × 106, is shown in
Table 1. It covered 67% of predicted specific mutations and 55% of predicted non-disruptive
mutations, as well as the wild-type residue at each position. We compared our Bfl-1-targeted
library to a Bim BH3-based library that was previously designed by hand using general
structural and chemical principles. The later lacked any intentional bias towards any pro-
survival protein(31). The computationally designed library exhibited improved PSSM scores
for Bfl-1 (Fig. 1e – h), as expected. Compared to the previously designed library, more
sequences were identified with higher Bfl-1 PSSM scores and lower Mcl-1 (Fig. 1e) or Bcl-
xL (Fig. 1f) PSSM scores. Only a few residues were predicted to impart specificity for Bfl-1
over Bcl-w and Bcl-2, so the difference between the two library PSSM score distributions
was modest for these proteins (Fig. 1g and h).
Previous studies showed that a PSSM model based on SPOT array intensities performed
well at predicting sequences specific for either Bcl-xL or Mcl-1(31). However, errors
associated with synthesis and array processing, and the simple additivity assumptions of
PSSMs, limit the predictive power of such models. Therefore, our library design strategy
was guided by the model but not tightly constrained by it. For example, only a few
mutations were predicted to confer specificity for Bfl-1 over Bcl-w. One design strategy
would be to require that at least one of these residues be included in all library members, but
this could be risky without verification of the influence of these residues on binding. Instead,
we identified all substitutions predicted to confer specificity against any of the four off-
target receptors, and required only that the library encode at least one specificity residue of
each type. We reasoned that this would maximize the diversity of available specificity
strategies, and the screening could identify good combinations. Even if no predictions were
correct for one or more particular binary specificity class (e.g. Bfl-1 over Bcl-w), as long as
other specificity predictions were accurate the library would still be sampling a useful
sequence space.
Library screening for peptides that bind Bfl-1—We used yeast-surface display to
identify Bfl-1-binding peptides (Fig. 2a)(34, 35). Surface-displayed Bim BH3 exhibited
strong binding to 100 nM of a soluble construct of Bfl-1 lacking the putative C-terminal
trans-membrane domain (Fig. 2b).
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Following transformation of the designed library into yeast, we performed fluorescence
activated cell sorting (FACS) for four rounds to identify clones that bound to Bfl-1 at 1 μM,
and a fifth round of screening at 100 nM Bfl-1 (Fig. 2c). Library populations after rounds 4
and 5 of positive screening did not exhibit binding to antibodies in the absence of Bfl-1, and
interaction with Bfl-1 was blocked in the presence of excess unlabeled Bim BH3
(Supplemental Fig 1), supporting binding to the same site.
Next, we used Illumina technology to sequence library pools from rounds 2, 4 and 5 of
sorting, and also a pool screened only for successful expression of BH3 peptides on the
yeast surface. Sequence logos are shown in Figure 2d. Figure 2e shows the distribution of
PSSMBfl-1 scores for the unselected library, and for populations from rounds 4 and 5. By
construction, wild-type Bim BH3 was assigned the highest possible PSSMBfl-1 score of 0
(see Methods). The PSSMBfl-1 scores for different pools were consistent with progressive
enrichment of the library in high-scoring sequences, and depletion of low scoring sequences,
indicating that PSSMBfl-1 scores were useful for recognizing non-binders and weak binders.
For example, despite the library optimization strategy, some residues classified as disruptive
were included due to codon choice. In most cases, these were subsequently removed in
screening (e.g. Asn at 2d, Asp and His at 3a, Asp and Pro at 3d; Table 1). However,
predicted disruptive residues were occasionally found in sequences identified by screening,
notably at positions 2e and 2g. Tyr at 2e occurred with high frequency in library binders,
contrary to the SPOT-based PSSM predictions. A peptide from round-4 selection with
tyrosine at 2e competed with fluorescent Bim BH3 binding to Bfl-1, although weakly
compared to wild-type Bim-BH3 (peptide FD3 in Supplemental Fig. 2).
Using the Illumina sequencing data, we tracked the enrichment of individual Bfl-1-binding
sequences over successive rounds. Wild-type Bim BH3 and clones FD1 and FD2 (Table 2)
were enriched over rounds 2, 4 and 5, and were also found in conventional sequencing of 96
clones from round 4 of screening (sequence logo in Supplemental Fig. 3). We synthesized
23-residue peptides corresponding to Bim BH3, FD1, and FD2, and measured binding to all
five pro-survival proteins using a fluorescence polarization assay that involved competition
with an 18-residue fluoresceinated Bim BH3 peptide (Table 2; Supplemental Fig. 4).
Consistent with the yeast-surface results, both FD1 and FD2 competed strongly with Bim
BH3 for binding to Bfl-1 (Ki values in Table 2). The slow off-rate observed for dissociation
of a 23-residue Bim BH3 peptide from Bfl-1 and Mcl-1 prevented us from measuring
accurate Ki values for these interactions. FD1 bound to all pro-survival proteins strongly,
although more weakly to Bcl-2, Bcl-w and Bcl-xL than to Bfl-1 and Mcl-1. FD2 exhibited
~4-60-fold specificity for Bfl-1 over Bcl-xL, Bcl-2 and Bcl-w, but bound very tightly to
Mcl-1. Overall these results indicated that high affinity Bfl-1 binders could be obtained by
screening for interaction with Bfl-1, but the peptides that were identified also bound tightly
to Mcl-1 and with variable affinities to other pro-survival proteins.
Competition screening for selective binders of Bfl-1—The yeast population after
four rounds of screening for Bfl-1 binding showed significant interaction with all five pro-
survival proteins at 100 nM (Supplemental Fig. 5). To identify the most selective binders in
this population, we introduced competition into the screening protocol. Bcl-xL and Mcl-1
represent distinct subclasses of pro-survival proteins in terms of sequence identity and
binding specificity, so we screened for Bfl-1-specific BH3 peptides by incubating the
round-4 sorted population with labeled Bfl-1 in the presence of 100-fold excess unlabeled
Bcl-xL and Mcl-1 (Figure 3). After three rounds of competition screening, the library clones
exhibited improved binding to Bfl-1 compared to both the initial starting population (round
4) and Bim BH3. Sequencing 94 clones from this population gave predominantly one
sequence (90 out of 94): FA1 (Table 2). On the surface of yeast, FA1 retained binding to 10
nM Bfl-1 in the presence of 100-fold excess Mcl-1 and Bcl-xL, in contrast to Bim (Figure 3;
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compare b and f). However, FA1 still displayed binding in the low nanomolar range to
Mcl-1 and Bcl-xL on the surface of yeast (Supplemental Fig. 6). Separately, we performed
competition screening for binding to Bfl-1 in the presence of excess unlabeled Bcl-xL or
Mcl-1 individually. These screens resulted in pools that were also dominated by clone FA1
(>90%).
In agreement with the PSSM models, we found that most clones from the round-4
population bound to Bcl-w at 100 nM (Supplemental Fig. 5). Therefore, we performed a
separate screen for binding to 10 nM Bfl-1 in the presence of excess unlabeled Bcl-w. After
two rounds of competition sorting, we isolated clones that did not bind to Bcl-w at 10 nM
(negative selection). Sequencing of 19 individual clones from this population resulted in 12
occurrences of sequence FW1 (Table 2: Supplemental Table 2).
We synthesized FA1 and FW1 as fluoresceinated 23-residue peptides. Very tight binding of
fluoresceinated FA1 to Bfl-1 and Mcl-1 precluded accurate determination of Kd values using
direct binding assays (data not shown). In addition, fluoresceinated FA1 showed extremely
slow dissociation from Bfl-1 in solution (t1/2 > 30 hours) (Supplemental Table 1). This is
probably because the yeast-surface display screening, which is done under non-equilibrium
conditions, selects for slow off-rates. Slow binding kinetics mean that solution equilibrium
binding measurements would require impractically long incubation times. Therefore, we
used bio-layer interferometry to further investigate the kinetics of binding of unlabelled FA1
(no dye) to Bfl-1 (Fig. 4A).
We again observed that the dissociation kinetics of Bfl-1 from surface-bound FA1 were
extremely slow. There was no detectable decrease in signal beyond the noise level for more
than 1000 seconds, providing an upper limit on koff of ~1.5 × 10–5 s−1.and an upper limit on
the Kd of ~0.3 nM. Thus, FA1 is a high-affinity binder of Bfl-1 with a half-life for
dissociation of > 12 hours. Dissociation of Mcl-1 and Bcl-xL from FA1 was faster, allowing
us to determine Kd values from bio-layer interferometry of ~6 and ~33 nM for these
proteins, respectively (Figure 4A). These data are consistent with FA1 being a selective
binder of Bfl-1.
To further quantify the binding of FA1 to the pro-survival proteins, we performed
competition experiments with fluoresceinated Bim-BH3 (Table 2: Supplemental Figure 4).
Except for the interaction of FA1 with Bfl-1, all mixtures were equilibrated in reasonable
times. Unlabeled FA1 competed with Bim-BH3 binding to each pro-survival protein, with
varying affinities (Ki values in Table 2). This experiment also indicated that FA1 bound to
the same hydrophobic groove as Bim BH3 on each protein.
The extremely slow off-rate for dissociation of FA1 from Bfl-1 made it difficult to quantify
the equilibrium binding specificity of this peptide in solution, although our data are
consistent with preferential binding to Bfl-1. The slow binding kinetics make the
equilibrium binding properties somewhat irrelevant, given that it is highly unlikely that
experiments using this reagent would be performed under equilibrium conditions. We have
established that FA1 will remain bound to Bfl-1 much longer than to any of the other pro-
survival proteins examined here. For possible in vivo applications of a Bfl-1 inhibitor, this
could be advantageous(36).
We measured the dissociation kinetics of fluoresceinated FW1 in solution and found that, in
contrast to FA1, FW1 had faster off rates for both Bfl-1 (t1/2 ~37 mins) and Mcl-1 (t1/2 ~3
hrs) (Supplemental Table 1). Competition binding studies using unlabeled FW1 showed that
this peptide was much more effective at competing with fluoresceinated Bim BH3 for
binding to Bfl-1 compared to Bcl-w, with a ~37-fold lower Ki for Bfl-1 compared to Bcl-w
(Table 2; Supplemental Figure 4). FW1 bound with sub-nanomolar affinity to Mcl-1, and
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with 20 – 30 nM affinity to Bcl-xL and Bcl-2, consistent with the screening protocol, which
included only Bcl-w as a competitor.
Modulating the affinity and specificity of FA1 through mutation—FA1 is a high-
affinity binder of Bfl-1 with a very slow dissociation rate. Its slow off-rate made it difficult
to analyze determinants of its binding specificity. We thus introduced a point mutation into
FA1 that adjusted its affinity into the range of many BH3 peptides derived from native
proteins(18, 22). Aspartate at position 3f is conserved in all natural BH3 proteins, and SPOT
arrays indicated that mutating this residue reduces binding to all receptors (which is why it
was not included in the screen)(31, 32). We introduced the mutation D3fK into FA1
(FA1_D3fK). The mutant naming convention here and below indicates the original residue,
the BH3 position that is the site of the substitution (as labeled in Fig. 1a), then the mutated
residue. Similar to FA1, FA1_D3fK competed with fluorescent Bim BH3 for binding to
Bfl-1, although at higher concentration compared to FA1 (Supplemental Fig. 7). We
determined that dye-labeled FA1_D3fK had a much faster off-rate for Bfl-1 (t1/2 ~ 5
minutes: Supplemental Table 1), so binding to all five receptors could be more readily
quantified.
FA1_D3fK bound to Bfl-1 with a Kd of ~47 nM, but bound to all the other receptors with Kd
> 1 μM (Figure 4B). Thus, FA1_D3fK is selective for Bfl-1.
There are three substitutions in FA1 compared to Bim: I3dA, E3gV and F4aL. We
quantified the contributions of the individual mutations to binding specificity in the context
of Bim_D3fK (Figure 4c). We first tested the influence of D3fK, which itself does not
confer specificity for Bfl-1 over Mcl-1 and Bcl-xL. Interestingly, this mutation provides
moderate specificity against Bcl-w. Asp at 3f in Bim BH3 interacts with a salt bridge triad
consisting of Asp 81, Asn 85 and Arg 88 (human Bfl-1 numbering) in several Bfl-1
structures(27, 28). Interestingly, Asp 81 in Bfl-1 is conserved between Bfl-1, Mcl-1, Bcl-xL
and Bcl-2, but not Bcl-w, which has a deletion at this site relative to other family members
(Fig. 5 a–c). Absence of a favorable electrostatic interaction between the introduced Lys and
Asp 81 may explain why the D3fK substitution destabilizes binding to Bcl-w more than to
other pro-survival proteins.
In the context of Bim_D3fK, I3dA significantly destabilized binding to Mcl-1, consistent
with SPOT arrays and previous observations that substitution at 3d in Bim-BH3 is not well
tolerated for Mcl-1 binding(31, 32). In contrast, Bfl-1, Bcl-xL, Bcl-2 and Bcl-w tolerate a
broad range of substitutions at the I3d position(30, 32). This tolerance may arise from small
structural adjustments that are possible in the α2/α3 region of the binding groove of these
proteins, near peptide position 3d(37). Fire et al. described variation in structures of Bcl-xL
bound to different peptides around this site(38), and Smits et al. described small variations in
the interactions of different peptides with Bfl-1(28). It is also interesting that Ile at Bim BH3
position 3d occupies a preferred rotamer when bound to Mcl-1 (rotamer probability 81% in
helices(39); PDB 2PQK(38)), which strongly prefers Ile at this site. But this residue is found
in low-probability rotamers in complexes with Bfl-1 (1% rotamer probability; PDB
2VM6(27)) and Bcl-xL (4% rotamer probability; PDB 3FDL(40)) This indicates some
frustration at this site, which may offset favorable hydrophobic interactions made by Ile with
these proteins, thereby minimizing the penalty of mutation from Ile to other residues.
Leucine at position 4a in Bim_D3fK stabilized binding to Mcl-1 and Bfl-1, relative to Bcl-
xL and Bcl-w, thereby providing specificity against Bcl-xL and Bcl-w at the expense of
specificity against Mcl-1. Mcl-1 is known to be highly tolerant to mutations at this site in
Bim BH3, and substitution of Phe with Val in Bim BH3 at 4a stabilizes binding to Mcl-1(31).
Structures of Bim BH3 and Puma BH3 bound to Bfl-1 allow a comparison of the
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interactions of Phe and Leu at 4a(28). As shown in Fig. 5d and 5e, the Leu residue of Puma
can fill an additional Bfl-1 pocket that is not accessible to Phe, likely explaining the
stabilizing effect of the Phe-to-Leu mutation in Bim D3fK.
The E3gV substitution did not significantly affect binding to any pro-survival protein in the
context of D3fK. We measured a modest 2.5-fold weakening of binding to Bcl-w and a
modest 2-fold increase in binding to Bfl-1. There is a glutamate residue at position 47 of
Bfl-1, very near the Bim BH3 3g site, and this residue is conserved as arginine in Bcl-xL,
Bcl-2 and Bcl-w (Fig. 5c). Thus, in peptide FA1, E3gV might confer a preference for Bfl-1
binding via an electrostatic mechanism. Interestingly, four peptides selected to be specific
for Bfl-1 over Bcl-w (FW2, FW3, FW4 and FW6) had a lysine substitution at 3g. Finally, in
a previous study(3), substitution of lysine with glutamate at 3g in Noxa conferred binding to
Bcl-xL and Bcl-w. Thus it appears that mutation of glutamate at position 3g may sometimes
contribute to a preference for binding Bfl-1.
PSSM predictions
We analyzed the results of our library design and experimental screening according to
predictions of the PSSM model. PSSMBfl-1 scores for all sequences in the library, and for
binders identified from screening, were strongly correlated with PSSM scores for binding to
the other pro-survival proteins Mcl-1, Bcl-xL, Bcl-2 and Bcl-w (Fig. 1e – h and Fig. 6a, b).
This indicates that most of the Bim BH3 sequence changes that satisfied our library design
requirements were predicted to have similar effects on many of the interactions.
Experimental binding profiles for yeast library populations after 4 or 5 rounds of sorting
supported a correlation of binding strengths, because clones selected for binding to Bfl-1
also exhibited significant binding to Mcl-1, Bcl-xL and Bcl-w at 100 nM (Supplemental Fig.
5).
Sequences obtained after screening only for binding (described by the logo in Fig. 2d) show
that all variable sites, including the boundary positions 2e, 2g and 3g, were occupied at high
frequency by large and/or hydrophobic residues. Competitive binding with Bim BH3
indicated that yeast-displayed peptides with these sequences bound specifically to the same
site on Bfl-1 (Supplemental Fig. 1). Large hydrophobic residue substitutions were predicted
to be favorable according to the SPOT array (Fig. 1c), but polar residues such as Arg, Lys,
Ser, Thr and Gln also had good PSSMBfl-1 scores yet were not observed with high
frequency. When we imposed a requirement for tighter binding to Bfl-1 and specific binding
to Bfl-1 over other pro-survival proteins (Mcl-1 and Bcl-xL, or Bcl-w), we isolated FA1 and
FW1 (Table 2). For FA1, position 2g was selected as Glu, rather than as one of the
predominant Phe/Trp/Val/Ile residues found after only positive screening, and FW1 had Gly
at this position. All three mutations observed in clone FA1 were predicted to be specific
over Mcl-1, Bcl-xL and Bcl-2 according to the PSSMs: Ala at 3d over Mcl-1; Val at 3g over
Mcl-1, Bcl-xL and Bcl-2; Leu at 4a over Bcl-xL (Table 1).
Very few experimentally identified binders had PSSMBfl-1 scores of less than −1.7 (Fig. 2d,
Fig. 6). But many sequences that were predicted to have high Bfl-1 scores (> −1) and lower
Mcl-1 or Bcl-xL scores (< −2), i.e. sequences scored in the off-diagonal, lower right side in
Figures 6a and b, did not appear among clones screened for Bfl-1 binding. Most sequences
in this region had Asn at 3a, and this mutation was not recovered in our screen. The model
also predicted that Lys/Tyr at position 2d and Ser at position 3d would provide specificity
over Mcl-1, and Lys/Arg at position 4a would provide specificity over Bcl-xL, but these
residues were either absent or present at a very low frequency after positive selection.
Illumina sequencing of expression-positive library cells (Fig. 2d) did not indicate any bias
against these residues prior to screening. Further studies would be required to determine
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whether the PSSM predictions are incorrect or whether aspects of the screen, or the
sequence context of the best binders, disfavored selection of these mutations.
Conclusions
The space of possible BH3-like peptide sequences is vast, so systematically uncovering
sequence-binding relationships in this protein family is challenging. We have carried out
several studies looking at how sequence variation in Bim BH3 influences binding to
different pro-survival proteins(31, 32, 43). The approach we present here, combining SPOT
array-guided computational design with experimental screening, was chosen to focus
experimental studies into interesting parts of the sequence space. We successfully identified
new BH3-like partners for Bfl-1, particularly the slowly-dissociating FA1 and the selective
binder FA1_D3fK. Our design strategy can be generalized to other Bcl-2 family complexes
and other types of protein-protein interaction systems and will lead to a better understanding
of binding specificities. In addition, peptides identified in this work hold potential to be used
as reagents for studying apopototic regulation.
Methods
PSSM model derived from SPOT array experiments
As previously described(31), the PSSM score for amino acid i at position j binding to a
specific pro-survival protein R, S(Ri,j), was obtained by taking the logarithm (log10) of the
ratio of the fluorescence intensity for the corresponding Bim BH3 point mutant to the
intensity of wild-type Bim BH3 (averaged over all wild-type spots) on the membrane.
Bfl-1 library design
For library design of Bfl-1, the Bfl-1 PSSM model was obtained by averaging the PSSM
scores derived from membranes probed with 100 nM and 1 μM of Bfl-1. The PSSM model
for Bcl-2 was obtained by the same procedure, and the model for Bcl-w was derived from a
membrane probed with 100 nM Bcl-w only(31). PSSM models for Bcl-xL and Mcl-1 were
described previously (we used the improved PSSM model using library SPOT arrays in
Dutta et al.(31)). Normalized intensities with values greater than 1 were capped at 1 before
deriving PSSM scores. The definition of non-disruptive residues and 4 different types of
specific residues is given in the Results. For a residue to be defined as specific, the
difference between its Bfl-1 PSSM score and its score for another receptor was required to
be larger than log10(1.5), and the residue also had to be in the top 33% when ranked by
PSSMBfl-1 – PSSMX for some X, where X is Bcl-xL, Mcl-1, Bcl-2 or Bcl-w. The native
residue was classified as both a non-disruptive and a specific residue for purposes of library
design. Because Met and Cys substitutions were not included on the membrane, their scores
were defined as those of Leu and Ser, respectively, when predicting non-disruptive residues.
However, these residues were not scored for the specificity predictions. In addition, Pro was
removed from consideration as a specific residue. Four quantities were defined for each
degenerate codon j at position i: (1) the size, sij, which is the number of unique tri-
nucleotides within the codon, (2) ndij, the number of non-disruptive residues encoded by the
codon, (3) spij, the number of specific residues (considering all 4 different types) encoded by
the codon, and (4) mij, the number of “misses” in chemical diversity for the codon. The
metric mij was defined for codons at positions 2d, 2g, 2e, 3b, 3a, 3d, 4a. Amino acids were
divided into different classes according to their physicochemical properties, and the number
of classes with no representation among the amino acids encoded by the codon was counted.
For the more buried positions 2d, 3a, 3d, 4a, the classes were [A], [L], [IV], [FY]. For the
more exposed positions 2g, 3b, 3g, the classes were [AG], [DE], [KR], [NQ], [ST]. A “miss”
was scored for a class only if at least one amino acid from that class was designated non-
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disruptive. A codon was considered more chemically diverse if it had a lower mij. At each
designed position, we only considered degenerate codons that encoded (1) the native Bim
BH3 amino acid and (2) at least one of each type of specific residue at that position (not
counting the native residue as a specific residue). The set of remaining degenerate codons
was trimmed further by comparing every pair of codons. If a degenerate codon had a larger
sij, a smaller spij, and a larger mij than another codon, then the first codon was considered
dominated by the second and was eliminated from the pool. The elimination process was
repeated until no degenerate codon dominated any other codon in the remaining set.
Optimization of degenerate codon combinations, out of the remaining pool of codons Di at
each designed position i, was performed by solving the following integer linear
programming problem:
Max ΣiΣj∈Di cij log(ndij) + ΣiΣj∈Di cij log(spij)
subject to ΣiΣj∈Di cij log(sij) <= 7
subject to ΣiΣj∈Di cij mij <= 4
subject to Σj∈Di cij = 1 for each position i
Where cij = 1 if codon j was picked at position i, and 0 otherwise. For the winner codon j
picked at each position i, Σilog(ndij) = log(Πindij) is the logarithm of the number of unique
protein sequences encoded with all designed positions occupied by non-disruptive residues,
Σilog(spij) = log(Πispij) is the logarithm of the number of unique protein sequences encoded
with all designed positions occupied by specific residues, and Σilog(sij) = log(Πisij) is the
logarithm of the library size (or the number of unique DNA sequences in the library) as
described in the text. Σimij is the total number of misses in chemical diversity across all
positions and we manually picked 4 as a threshold. The problem was solved using the glpsol
solver in the GLPK package (GNU MathProg).
Expression and purification of pro-survival proteins
All pro-survival proteins were purified as described previously, and the constructs used were
the same as in that work(31, 32).
Library construction—Construction of the yeast display vector used in this study was
described previously(31). The combinatorial library was constructed using homologous
recombination in yeast. The wild-type Bim-BH3 gene was randomized using the mutagenic
forward primer (5' GGCCGTCCGGAAATTTGG WWK BMT CAG DDK VWC CGT CGT
NNT GGC GAT VHA WDK AATGCGTATTATGCGCGTCGC 3'; N represents a mixture
of A, T, G and C; W represents a mixture of A and T; K represents a mixture of G and T; B
represents a mixture of C, G and T; M a mixture of A and C; D represents a mixture of A, G
and T; V represents a mixture of A, C and G; H represents a mixture of A, C and T;) and a
reverse primer (5' CTAAAAGTACAGTGGGAACAAAGTCG 3'). The PCR product was
further extended at the 5' end to provide overlapping ends of more than 50 base pairs to
increase transformation efficiency(44). The amplified product was purified using a PCR
purification kit (Qiagen), and transformed into yeast along with an acceptor vector cut with
Nhe1 and Xho1. Transformation was done using electroporation following an established
protocol(45).
Yeast display and FACS screening—Yeast cells were analyzed in a BD FACScan or
BD FacsCalibur flow cytometer powered by CellQuest software. For the first five rounds of
positive sorting against myc- tagged Bfl-1, yeast library cells were prepared and labeled as
described previously(31). Library cells after 4 rounds of positive sorting were further sorted
for specific binding to Bfl-1 using competition. For competition sorts, all pro-survival
proteins (tagged Bfl-1 and untagged competitors) were first mixed together and then added
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to the cells. To sort cells displaying peptides specific for Bfl-1 over Bcl-xL and Mcl-1, 2 ×
107 library yeast cells from the 4th round were mixed with 100 nM Bfl-1 in the presence of
500 nM of His-tagged Bcl-xL and 500 nM untagged Mcl-1 in 50 mM Tris, 100 mM NaCl
pH 8.0. Mixtures were incubated for at least 2 hours. All subsequent steps were performed
with ice-cold buffer. After washing off unbound receptor with the same buffer, cells were
labeled with primary antibodies (anti-FLAG rabbit and anti-c-myc mouse) (Sigma) followed
by washing and labeling with secondary antibodies (fluorescein (FITC)-conjugated goat
anti-rabbit antibody and R-Phycoerythrin (PE)-conjugated goat anti-mouse IgG (Sigma) or
an allophycocyanin (APC) labeled goat anti-mouse IgG (BD Biosciencecs)). In the first
round of competition selection, ~1% of the expression positive population was collected. In
subsequent rounds, incubation was done with 10 nM Bfl-1 in the presence of 500 nM Bcl-xL
and 500 nM Mcl-1, and the sorting gate was reduced to collect 0.2–0.5% of the expression-
positive population. For competition screens against only Bcl-xL or only Mcl-1, a similar
protocol was followed except that library yeast cells from the 4th round were mixed with 100
nM Bfl-1 in the presence of either 500 nM of His-tagged Bcl-xL or 500 nM untagged Mcl-1
separately, and the top ~1–2% of the expression-positive population was collected. Two
subsequent competition screens were done in the presence of 10 nM Bfl-1 and 500 nM Bcl-
xL or 500 nM Mcl-1. For Bcl-xL, one further round was performed in the presence of 10 nM
Bfl-1 and 1 μM Bcl-xL. Two rounds of competition screening including Bcl-w were
performed with the round-4 population, using 10 nM Bfl-1 in the presence of 10 μM
untagged Bcl-w. To further eliminate Bcl-w binding peptides, we followed the competition
sorts with a negative sort for cells that did not bind to 10 nM Myc-tagged Bcl-w. Analysis of
the library population for binding to different pro-survival proteins was performed using
FITC fluorescence for expression and APC fluorescence to observe binding. Sorting of yeast
cells was performed in a BD FacsAria or Cytomation MoFlo using 488 nm and/or 561 nm
excitation.
Peptide synthesis and biotinylation—All unlabelled and fluoresceinated peptides
were synthesized by the MIT Biopolymers Laboratory. Fluoresceinated Bim–BH3 used for
fluorescence polarization was 18 residues long. All other Bim BH3 peptides variants used in
this study were 23 residues long. Peptides were purified using reverse phase HPLC with a
C18 column and a linear water/acetonitrile gradient. Peptides for fluorescence polarization
binding assays had N-acetylated and C-amidated ends, with the exception of FD2, which
had free ends for improved solubility. For bio-layer interferometry, peptide FA1 (23
residues) was synthesized with a free N terminus and an amidated C-terminus and
biotinylated using the EZ-link NHS-PEG4-biotin from Thermo Scientific using the
manufacturer's protocol. The biotinylation reaction was performed at room temperature for
30–60 minutes, following which the biotinylated peptide was purified using reverse phase
HPLC with a C18 column. The mass of the biotinylated peptide was confirmed by mass
spectrometry.
Bio-layer interferometry studies—All experiments were performed using the BLITZ
system from ForteBio. Biotinylated FA1 at a concentration of 0.1 mg/ml was captured on
Streptavidin (SA) biosensors (ForteBio) to levels of ~0.42 response units. Pro-survival
proteins Bfl-1, Mcl-1 and Bcl-xL, at 2–3 concentrations ranging from 30–250 nM, were
bound to FA1 for 10 minutes and then allowed to dissociate in phosphate buffer (20 mM
phosphate, 50 mM sodium chloride, 0.1% BSA, pH 7.5). Dissociation was monitored over
60 minutes for Bfl-1 and Mcl-1 and over 10 minutes for Bcl-xL. From the dissociation phase
data for Bfl-1 binding, an upper bound on the off-rate was estimated from the fluctuation in
signal over 1000 seconds. Dissociation phase data for Mcl-1 and Bcl-xL were fit to the
reaction RUt = Aexp(−kofft) + RUbase where RUt is the observed response unit, A is the
amplitude of the signal, koff is the rate constant for dissociation, t is the time and RUbase is
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an added parameter to account for change in baseline after dissociation of the ligand(46). All
three parameters A, koff and RUbase were fit. The association phase was fit to the equation
RUt = RUbase + CkonRmax[1-exp(−Bt)]/B where B = Ckon+koff, RUt is the observed
response units, C is the concentration of the pro-survival protein, kon is the on rate constant,
koff is the off rate constant, Rmax is the capacity of the peptide immobilized on the biosensor.
The three parameters RUbase, kon and Rmax were fit, and off-rate parameters were taken
from the dissociation analysis. Analysis of kinetic data was performed using Igor Pro 6.02A
(Wavemetrics).
Fluorescence polarization binding assays—Both direct and competition binding
assays were done at 37 ⍛C in 20 mM sodium phosphate, 50 mM NaCl, 1 mM
ethylenediaminetetraacetic acid, 0.001% triton X (v/v), and 5% DMSO (v/v), pH 7.8].
Concentrations of labeled and unlabeled peptides are given in Table 2. The dissociation half-
lives of fluorescently labeled peptides for different pro-survival proteins (reported in
Supplementary Table 1) were measured by monitoring the decrease in anisotropy with time
after addition of excess unlabeled Bim (1 μM) to a premixed solution of 10–20 nM of
fluoresceinated peptide with 50–100 nM of individual pro-survival proteins. Data were fit to
a single exponential given by the equation RUt = Aexp(−kofft) + RUbase as described above.
For direct-binding assays, pro-survival proteins were first serially diluted in a 96-well plate
followed by the addition of the fluorescently labeled peptides. The plates were incubated at
37 °C for 4–6 hours before reading. For competition binding assays, unlabeled peptides and
fluorescently labeled peptides were incubated for 10 minutes before the relevant pro-
survival protein was added to the mixture. The plates were incubated at 37 ⍛C and the
anisotropy monitored over a time period of 4–24 hours. Due to the extremely slow off rates
observed for the 23-mer Bim-BH3 peptide for Bfl-1 and Mcl-1 and for 23-mer FA1 for
Bfl-1, we do not report Ki values for these interactions. However, we did not observe any
significant change in anisotropy after 4 hours of incubation. Measurements with longer
equilibration times were not reliable due to loss of signal of the free fluorescent peptide over
time. Direct binding data were fit to a model for single-site binding as described
previously(47). Competition binding data were fit to a model that considered depletion of the
labeled and unlabeled peptide as described previously(31, 48). Curve fitting was performed
using the program Igor Pro 6.02A (Wavemetrics).
Illumina sequencing of library pools—Illumina sample preparation and data analysis
were described previously(32). Briefly, DNA was extracted from yeast library cells using
Zymoprep Yeast Plasmid Miniprep I kit (Zymoresearch). Following PCR amplification
using High Fidelity Taq DNA polymerase (Invitrogen), the product was purified using the
Qiagen PCR purification kit. Sample purity was checked using the Agilent 2100
BioAnalyzer at the MIT BioMicro Center. Sequencing was performed using the Illumina
HiSeq system. Only sequences with Illumina quality scores with an overall confidence of
0.995 over all the variable nucleotides in a read were considered. For sequence logo
construction in Figure 2, only unique sequences that occurred 20 or more times in each
library pool after 2, 4 and 5 rounds of positive screening were included.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Computational library design. (a) Bim BH3 with residue numbering using a heptad
convention. (b) Bim BH3 in complex with Bfl-1 (PDB ID: 2VM6)(27). Bfl-1 is shown in
surface representation colored by atom type. Side chains of residues on Bim BH3 that were
randomized in the library are shown as sticks. (c) Substitution SPOT array image of Bim
BH3 point mutants binding to 100 nM Bfl-1(32). The rows indicate the substituted positions
and the columns indicate mutations. The leftmost column corresponds to Bim BH3. (d)
Steps in the procedure for designing a library of peptides to target Bfl-1 in preference to
other pro-survival proteins. (e–f) Correlation of PSSMBfl-1 scores for library sequences with
scores from (e) PSSMMcl-1, (f) PSSMBcl-xL, (g) PSSMBcl-w and (h) PSSMBcl-2 shown as
contour plots for the computationally designed library (color) and the manually designed
library of Dutta et al.(31) (gray). The plots were generated using a smoothing routine in
MATLAB(33).
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Yeast-surface display screening to obtain BH3 peptides that bind to Bfl-1. (a) Schematic of
the yeast-surface display system used to screen a BH3 peptide library. BH3 peptides were
expressed as fusions to the yeast cell surface protein Aga2 and detected using FITC
fluorescence. Binding to Myc tagged Bfl-1 was monitored using APC fluorescence. (b)
Strong binding of surface displayed Bim-BH3 peptide to 100 nM Bfl-1 illustrated by the
correlation between FITC fluorescence (expression axis) and APC fluorescence (binding
axis). (c) Enrichment of Bfl-1 binding to the yeast library through successive rounds of cell
sorting. FACS plots of different populations are shown binding to 100 nM Bfl-1. (d)
Sequence logo for clones obtained from Illumina sequencing of yeast cells that were
expression positive or present at least twenty times in each of positive selection rounds 2, 4
and 5. The numbering of the randomized positions and the wild-type sequence are shown at
the bottom. (e) Distribution of PSSMBfl-1 scores for the entire theoretical library and the
library after two different stages of screening. Wild-type Bim BH3 has the highest possible
PSSM score of 0.
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FACS tests for specific binding to Bfl-1. FACS profiles for Bfl-1 binding to Bim BH3 (a and
b), the library after four rounds of positive selection for Bfl-1 (c and d), or clone FA1 (e and
f). Bfl-1 was at 10 nM. Analysis was without (left, panels a, c, e) or with (right, panels b, d,
f) 500 nM each of unlabeled Bcl-xL and Mcl-1. Cell populations displaying BH3 peptides
that showed preferential binding to Bfl-1 over Bcl-xL and Mcl-1 are quantified as a
percentage of the total population in panels c and d.
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Equilibrium and kinetic binding data for engineered BH3 peptides. (a) Kinetic analysis of
peptide FA1 binding to Bfl-1, Mcl-1 and Bcl-xL proteins using the BLITZ bio-layer
interferometry system. The peptide was immobilized to a streptavidin biosensor through a
biotin at the amino terminus. The protein concentration was 62.5 nM for all three
experiments. Errors represent standard deviations from the mean of three independent
experiments. (b) Direct binding of fluorescently labeled FA1_D3fK to Bfl-1, Mcl-1, Bcl-xL,
Bcl-w and Bcl-2. The sequence of FA1_D3fK is shown at the top. The concentration of
fluoresceinated FA1_D3fK was 10 nM. Average Kd values from a minimum of three
experiments are shown with errors corresponding to the standard deviations over replicates.
(c) The dissociation constants of different mutants of Bim BH3 for binding to Bfl-1 (red),
Mcl-1 (blue), Bcl-xL (green) and Bcl-w (purple) are shown. The mutations are shown at the
bottom.
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(a) Electrostatic interactions between aspartate at position 3f of Bim BH3 (green) with
residues Asp 81, Asn 85 and Arg 88 in Bfl-1 (cyan) in the human Bfl-1: Bim (PDB code
2VM6(27)). (b) Structural alignment of Bcl-w (PDB code 1O0L(41)) with the Bfl-1: Bim
complex shown in (a). Bfl-1 is omitted for clarity. The corresponding residues are labeled as
in (a) to emphasize the missing aspartate. (c) Structure-based sequence alignment using
DALI(42) of human Bfl-1 and Bcl-w highlighting the residue changes discussed in the text.
Glu 47 in Bfl-1 near the Bim BH3 3g site is substituted with an Arg in Bcl-w and is shown
shaded in grey. (d–e) The hydrophobic pocket surrounding position 4a in the Bim:Bfl-1
structure (PDB code 2VM6(27)) (d) and the Bfl-1: Puma structure (PDB code 2VOF(28)) (e)
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Distribution of PSSM scores for selected library sequences. (a) Correlation of PSSMBfl-1
with PSSMMcl-1 scores, and (b) PSSMBfl-1 with PSSMBcl-xL scores. The distribution of
scores for the theoretical library is shown as a contour plot(33). Sequences present at least
once in all three library pools from positive screening rounds 2, 4 and 5 were scored for
interaction with Bfl-1, Mcl-1 or Bcl-xL and are shown as points overlaid on top of the
contour. Scores for FA1 and FA1_D3fK are shown using red and black circles, respectively.
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Table 1
Bfl-1 library design results




vs. Bcl-xL vs. Mcl-1 vs. Bcl-2 vs. Bcl-w
I2d ACFGHIKMLPRTVWY - WKY - - FIKLMNYZ (WWK) -
A2e ACGHPS HS H - ADHPSY (BMT) Y and D
E2g ACDEFGHIKNQRSTWY Y FGHIKVY - GT CDEFGIKLMNRSVWYZ (DDK) L and M
L3a FILMNV NV N N N DHILNV (VWC) -
R3b AKQR - - - - Not randomized
I3d ACFGHIMKLNQRSTVY - AFGHKNQRSTVY - - ACDFGHILNPRSTVY (NNT) -
G3e G - - - - Not randomized
D3f D - - - - Not randomized
E3g ACDEFGHIKLMNQRSTVWY AFHIKLNRQSTVWY AFILWVY FIKLRVWY - AEIKLPQTV (VHA) -
F4a ACFGHIKLMNQRSTVWY AGHIKLQRSTW - K KR CFIKLMNRSWYZ (WDK) -
a
Disruptive residues included as a result of codon choice are underlined. Codons used for library construction are shown in parentheses
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Table 2
Sequences and binding data for natural and engineered BH3 peptides.
Fluorescent Peptide(18 residues) Sequence Kd (nM)
Bfl-1 Mcl-1 Bcl-xL Bcl-w Bcl-2
Bim IWIAQELRRIGDEFNAYY 4 ± 1 0.8 ± 0.4 6 ± 1 15 ± 3 5 ± 1
Unlabeled peptides (23 residues) 2 3 4 Ki (nM)
defgabcdefgabcdefg
Bim RPEIWIAQELRRIGDEFNAYYAR NE NE 0.11 ± 0.03 2 ± 0.3 0.8 ± 0.1
FD1 RPEIWLAQYLRRLGDQINAYYAR 0.7 ± 0.2 0.1 ± 0.02 5 ± 0.4 12 ± 3 7 ± 0.8
FD2 RPEIWMAQVLRRFGDLLNAYYAR 3.8 ± 0.7 1 ± 0.1 18 ± 0.2 104 ± 19 223 ± 16
FA1 RPEIWIAQELRRAGDVLNAYYAR NE 1 ± 0.1 8 ± 0.2 2 ± 1 313 ± 8
FW1 RPEIWIAQGLRRIGDTWNAYYAR 8 ± 2 0.2 ± 0.04 20 ± 4 298 ± 41 31 ± 7
aConcentration of fluoresceinated Bim was 10 nM in all experiments.
bConcentration of pro-survival protein was 50 nM for competition fluorescence polarization experiments.
c
Error bars are standard deviations from the mean of a minimum of three experiments.
aNE: Not Equilibrated. Ki values are not reported for these interactions due to extremely slow off rates leading to impractically long incubation
times to reach equilibrium (see Supplemental Table 2).
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